Thuny F, Grisoli D, Collart F et al. Management of infective endocarditis: challenges and perspectives. Lancet, 2012; 379: 965-975.
Habib G. Management of infective endocarditis. Heart, 2006; 92: 124-130.
Horstkotte D, Follath F, Gutschik E et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary: the Task Force on Infective Endocarditis of the European Society of Cardiology. Eur Heart J, 2004; 25: 267-276.
Naber CK, Erbel R, Baddour LM, Horstkotte D. New guidelines for infective endocarditis: a call for collaborative research. Int J Antimicrob Agents, 2007; 29: 615-616.
Wilson W, Taubert KA, Gewitz M et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation, 2007; 116: 1736-1754.
Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation, 2005; 111: e394-e434.
Nishimura RA, Carabello BA, Faxon DP et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation, 2008; 118: 887-896.
Habib G, Hoen B, Tornos P et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J, 2009; 30: 2369-2413.
Kang DH, Kim YJ, Kim SH et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med, 2012; 366: 2466-2473.
Bruun NE, Habib G, Thuny F, Sogaard P. Cardiac imaging in infectious endocarditis. Eur Heart J, 2014; 35: 624-632.
Lancellotti P, Rosenhek R, Pibarot P et al. ESCWorking Group on Valvular Heart Disease position paper - heart valve clinics: organization, structure, and experiences. Eur Heart J, 2013; 34: 1597-1606.
Botelho-Nevers E, Thuny F, Casalta JP et al. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med, 2009; 169: 1290-1298.
Duval X, Leport C. Prophylaxis of infective endocarditis: current tendencies, continuing controversies. Lancet Infect Dis, 2008; 8: 225-232.
Danchin N, Duval X, Leport C. Prophylaxis of infective endocarditis: French recommendations 2002. Heart, 2005; 91: 715-718.
Lockhart PB, Brennan MT, Sasser HC et al. Bacteremia associated with toothbrushing and dental extraction. Circulation, 2008; 117: 3118-3125.
Veloso TR, Amiguet M, Rousson V et al. Induction of experimental endocarditis by continuous low-grade bacteremia mimicking spontaneous bacteremia in humans. Infect Immun, 2011; 79: 2006-2011.
Van der Meer JT, Van Wijk W, Thompson J et al. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. Lancet, 1992; 339: 135-139.
Lacassin F, Hoen B, Leport C et al. Procedures associated with infective endocarditis in adults. A case control study. Eur Heart J, 1995; 16: 1968-1974.
Strom BL, Abrutyn E, Berlin JA et al. Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. Ann Intern Med, 1998; 129: 761-769.
Duval X, Alla F, Hoen B et al. Estimated risk of endocarditis in adults with predisposing cardiac conditions undergoing dental procedures with or without antibiotic prophylaxis. Clin Infect Dis, 2006; 42: e102-e107.
Lee P, Shanson D. Results of a UK survey of fatal anaphylaxis after oral amoxicillin. J Antimicrob Chemother, 2007; 60: 1172-1173.
Glenny AM, Oliver R, Roberts GJ et al. Antibiotics for the prophylaxis of bacterial endocarditis in dentistry. Cochrane Database Syst Rev, 2013; 10: CD003813.
Gould FK, Elliott TS, Foweraker J et al. Guidelines for the prevention of endocarditis: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother, 2006; 57:1035-1042.
Daly CG, Currie BJ, Jeyasingham MS et al. A change of heart: the new infective endocarditis prophylaxis guidelines. Aust Dent J, 2008; 53: 196-200.
Nishimura RA, Otto CM, Bonow RO et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014; 63: 2438-2488.
Naber C, Al Nawas B, Baumgartner H et al. Prophylaxe der infektiösen Endokarditis. Der Kardiologe, 2007; 1: 243-250.
Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures (CG64). National Institute for Health and Care Excellence (NICE). http://www.nice.org.uk/guidance/CG64
Mohindra RK. A case of insufficient evidence equipoise: the NICE guidance on antibiotic prophylaxis for the prevention of infective endocarditis. J Med Ethics, 2010; 36: 567-570.
Chambers JB, Shanson D, Hall R et al. Antibiotic prophylaxis of endocarditis: the rest of the world and NICE. J R Soc Med, 2011; 104: 138-140.
Thornhill M, Dayer M, Forde J et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ, 2011; 342: d2392.
Dayer MJ, Chambers JB, Prendergast B et al. NICE guidance on antibiotic prophylaxis to prevent infective endocarditis: a survey of clinicians' attitudes. QJM, 2013; 106: 237-243.
Dayer MJ, Jones S, Prendergast B et al. Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. Lancet, 2015; 385: 1219-1228.
Duval X, Delahaye F, Alla F et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol, 2012; 59: 1968-1976.
Desimone DC, Tleyjeh IM, Correa de Sa DD et al. Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines. Circulation, 2012; 126: 60-64.
Pasquali SK, He X, Mohamad Z et al. Trends in endocarditis hospitalizations at US children's hospitals: impact of the 2007 American Heart Association Antibiotic Prophylaxis Guidelines. Am Heart J, 2012; 163: 894-899.
Pant S, Patel NJ, Deshmukh A et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol, 2015; 65: 2070-2076.
Lalani T, Chu VH, Park LP et al. In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med, 2013; 173: 1495-1504.
Baumgartner H, Bonhoeffer P, De Groot NM et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J, 2010; 31: 2915-2957.
Knirsch W, Nadal D. Infective endocarditis in congenital heart disease. Eur J Pediatr, 2011; 170: 1111-1127.
Sherman-Weber S, Axelrod P, Suh B et al. Infective endocarditis following orthotopic heart transplantation: 10 cases and a review of the literature. Transpl Infect Dis, 2004; 6: 165-170.
Findler M, Chackartchi T, Regev E. Dental implants in patients at high risk for infective endocarditis: a preliminary study. Int J Oral Maxillofac Surg, 2014; 43: 1282-1285.
Regitz-Zagrosek V, Blomstrom LC, Borghi C et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J, 2011; 32: 3147-3197.
Yu CH, Minnema BJ, Gold WL. Bacterial infections complicating tongue piercing. Can J Infect Dis Med Microbiol, 2010; 21: e70-e74.
de Oliveira JC, Martinelli M, Nishioka SA et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol, 2009; 2: 29-34.
van Rijen MM, Bode LG, Baak DA et al. Reduced costs for Staphylococcus aureus carriers treated prophylactically with mupirocin and chlorhexidine in cardiothoracic and orthopaedic surgery. PLoS One, 2012; 7: e43065.
Bode LG, Kluytmans JA, Wertheim HF et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med, 2010; 362: 9-17.
Recommendations on the management of oral dental foci of infection. French Society of Oral Surgery. http://www.societechirorale.com/documents/Recommandations/foyers-infectieux-argument-EN.pdf
Goldmann DA, Hopkins CC, Karchmer AW et al. Cephalothin prophylaxis in cardiac valve surgery. A prospective, double-blind comparison of two-day and six-day regimens. J Thorac Cardiovasc Surg, 1977; 73: 470-479.
Fernandez-Hidalgo N, Almirante B, Tornos P et al. Contemporary epidemiology and prognosis of health care-associated infective endocarditis. Clin Infect Dis, 2008; 47: 1287-1297.
Selton-Suty C, Celard M, Le MV et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year populationbased survey. Clin Infect Dis, 2012; 54: 1230-1239.
Benito N, Miro JM, de Lazzari E et al. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med, 2009; 150: 586-594.
Slipczuk L, Codolosa JN, Davila CD et al. Infective endocarditis epidemiology over five decades: a systematic review. PLoS One, 2013; 8: e82665.
Tornos P, Iung B, Permanyer-Miralda G et al. Infective endocarditis in Europe: lessons from the Euro Heart Survey. Heart, 2005; 91: 571-575.
Vahanian A, Alfieri O, Andreotti F et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J, 2012; 33: 2451-2496.
Chirillo F, Scotton P, Rocco F et al. Impact of a multidisciplinary management strategy on the outcome of patients with native valve infective endocarditis. Am J Cardiol, 2013; 112: 1171-1176.
Thuny F, Giorgi R, Habachi R et al. Excess mortality and morbidity in patients surviving infective endocarditis. Am Heart J, 2012; 164: 94-101.
Thuny F, Di Salvo G, Belliard O et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation, 2005; 112: 69-75.
Perez de Isla L, Zamorano J, Lennie V et al. Negative blood culture infective endocarditis in the elderly: long-term follow-up. Gerontology, 2007; 53: 245-249.
Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care, 2010; 14: R15.
Yu CW, Juan LI, Hsu SC et al. Role of procalcitonin in the diagnosis of infective endocarditis: a meta-analysis. Am J Emerg Med, 2013; 31: 935-941.
Polewczyk A, Janion M, Podlaski R, Kutarski A. Clinical manifestations of lead-dependent infective endocarditis: analysis of 414 cases. Eur J Clin Microbiol Infect Dis, 2014; 33: 1601-1608.
Habib G, Avierinos JF, Thuny F. Aortic valve endocarditis: is there an optimal surgical timing? Curr Opin Cardiol, 2007; 22: 77-83.
Habib G, Badano L, Tribouilloy C et al. Recommendations for the practice of chocardiography in infective endocarditis. Eur J Echocardiogr, 2010; 11: 202-219.
Mugge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. J Am Coll Cardiol, 1989; 14: 631-638.
Rasmussen RV, Host U, Arpi M et al. Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of screening with echocardiography. Eur J Echocardiogr, 2011; 12: 414-420.
Incani A, Hair C, Purnell P et al. Staphylococcus aureus bacteraemia: evaluation of the role of transoesophageal echocardiography in identifying clinically unsuspected endocarditis. Eur J Clin Microbiol Infect Dis, 2013; 32: 1003-1008.
Daniel WG, Mugge A, Martin RP et al. Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl J Med, 1991; 324: 795-800.
Sochowski RA, Chan KL. Implication of negative results on a monoplane transesophageal echocardiographic study in patients with suspected infective endocarditis. J Am Coll Cardiol, 1993; 21: 216-221.
Karalis D, Chandrasekaran K, Wahl J et al. Transesophageal echocardiographic recognition of mitral valve abnormalities associated with aortic valve endocarditis. Am Heart J, 1990; 119: 1209-1211.
Pedersen WR, Walker M, Olson JD et al. Value of transesophageal echocardiography as an adjunct to transthoracic echocardiography in evaluation of native and prosthetic valve endocarditis. Chest, 1991; 100: 351-356.
Vilacosta I, Graupner C, San Roman JA et al. Risk of embolization after institution of antibiotic therapy for infective endocarditis. J Am Coll Cardiol, 2002; 39: 1489-1495.
Shapira Y, Weisenberg DE, Vaturi M et al. The impact of intraoperative transesophageal echocardiography in infective endocarditis. Isr Med Assoc J, 2007; 9: 299-302.
Sanchez-Enrique C, Vilacosta I, Moreno HG et al. Infected marantic endocarditis with leukemoid reaction. Circ J, 2014; 78: 2325-2327.
Eudailey K, Lewey J, Hahn RT, George I. Aggressive infective endocarditis and the importance of early repeat echocardiographic imaging. J Thorac Cardiovasc Surg, 2014; 147: e26-e28.
Berdejo J, Shibayama K, Harada K et al. Evaluation of vegetation size and its relationship with embolism in infective endocarditis: a real-time 3-dimensional transesophageal echocardiography study. Circ Cardiovasc Imaging, 2014; 7: 149-154.
Liu YW, Tsai WC, Lin CC et al. Usefulness of real-time three-dimensional echocardiography for diagnosis of infective endocarditis. Scand Cardiovasc J, 2009; 43: 318-323.
Hekimian G, Kim M, Passefort S et al. Preoperative use and safety of coronary angiography for acute aortic valve infective endocarditis. Heart, 2010; 96: 696-700.
Feuchtner GM, Stolzmann P, Dichtl W et al. Multislice computed tomography in infective endocarditis: comparison with transesophageal echocardiography and intraoperative findings. J Am Coll Cardiol, 2009; 53: 436-444.
Fagman E, Perrotta S, Bech-Hanssen O et al. ECG-gated computed tomography: a new role for patients with suspected aortic prosthetic valve endocarditis. Eur Radiol, 2012; 22: 2407-2414.
Goddard AJ, Tan G, Becker J. Computed tomography angiography for the detection and characterization of intra-cranial aneurysms: current status. Clin Radiol, 2005; 60: 1221-1236.
Huang JS, Ho AS, Ahmed A et al. Borne identity: CT imaging of vascular infections. Emerg Radiol, 2011; 18: 335-343.
Snygg-Martin U, Gustafsson L, Rosengren L et al. Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical brain damage markers. Clin Infect Dis, 2008; 47: 23-30.
Cooper HA, Thompson EC, Laureno R et al. Subclinical brain embolization in left-sided infective endocarditis: results from the evaluation by MRI of the brains of patients with left-sided intracardiac solid masses (EMBOLISM) pilot study. Circulation, 2009; 120: 585-591.
Duval X, Iung B, Klein I et al. Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: a prospective study. Ann Intern Med, 2010; 152: 497-504, W175.
Okazaki S, Yoshioka D, Sakaguchi M et al. Acute ischemic brain lesions in infective endocarditis: incidence, related factors, and postoperative outcome. Cerebrovasc Dis, 2013; 35: 155-162.
Li JS, Sexton DJ, Mick N et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis, 2000; 30: 633-638.
Iung B, Tubiana S, Klein I et al. Determinants of cerebral lesions in endocarditis on systematic cerebral magnetic resonance imaging: a prospective study. Stroke, 2013; 44: 3056-3062.
Goulenok T, Klein I, Mazighi M et al. Infective endocarditis with symptomatic cerebral complications: contribution of cerebral magnetic resonance imaging. Cerebrovasc Dis, 2013; 35: 327-336.
Hess A, Klein I, Iung B et al. Brain MRI findings in neurologically asymptomatic patients with infective endocarditis. AJNR Am J Neuroradiol, 2013; 34: 1579-1584.
Iung B, Klein I, Mourvillier B et al. Respective effects of early cerebral and abdominal magnetic resonance imaging on clinical decisions in infective endocarditis. Eur Heart J Cardiovasc Imaging, 2012; 13: 703-710.
Palestro CJ, Brown ML, Forstrom LA et al. Society of Nuclear Medicine Procedure Guideline for 99mTc-exametazime (HMPAO)-labeled leukocyte scintigraphy for suspected infection/inflammation, version 3.0, 2004. HMPAO-v3 pdf 2004.
Saby L, Laas O, Habib G et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol, 2013; 61: 2374-2382.
Erba PA, Conti U, Lazzeri E et al. Added value of 99mTc-HMPAO-labeled leukocyte SPECT/CT in the characterization and management of patients with infectious endocarditis. J Nucl Med, 2012; 53: 1235-1243.
Rouzet F, Chequer R, Benali K et al. Respective performance of 18F-FDG PET and radiolabeled leukocyte scintigraphy for the diagnosis of prosthetic valve endocarditis. J Nucl Med, 2014; 55: 1980-1985.
La Scola B, Raoult D. Direct identification of bacteria in positive blood culture bottles by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry. PLoS One, 2009; 4: e8041.
Raoult D, Casalta JP, Richet H et al. Contribution of systematic serological testing in diagnosis of infective endocarditis. J Clin Microbiol, 2005; 43: 5238-5242.
Fournier PE, Thuny F, Richet H et al. Comprehensive diagnostic strategy for blood culture-negative endocarditis: a prospective study of 819 new cases. Clin Infect Dis, 2010; 51: 131-140.
Loyens M, Thuny F, Grisoli D et al. Link between endocarditis on porcine bioprosthetic valves and allergy to pork. Int J Cardiol, 2013; 167: 600-602.
Habib G, Derumeaux G, Avierinos JF et al. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol, 1999; 33: 2023-2029.
Hill EE, Herijgers P, Claus P et al. Abscess in infective endocarditis: the value of transesophageal echocardiography and outcome: a 5-year study. Am Heart J, 2007; 154: 923-928.
Vieira ML, Grinberg M, Pomerantzeff PM et al. Repeated echocardiographic examinations of patients with suspected infective endocarditis. Heart, 2004; 90: 1020-1024.
Thuny F, Gaubert JY, Jacquier A et al. Imaging investigations in infective endocarditis: current approach and perspectives. Arch Cardiovasc Dis, 2013; 106: 52-62.
Gahide G, Bommart S, Demaria R et al. Preoperative evaluation in aortic endocarditis: findings on cardiac CT. AJR Am J Roentgenol, 2010; 194: 574-578.
Thuny F, Avierinos JF, Tribouilloy C et al. Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multicentre study. Eur Heart J, 2007; 28: 1155-1161.
Hyafil F, Rouzet F, Lepage L et al. Role of radiolabelled leucocyte scintigraphyin patients with a suspicion of prosthetic valve endocarditis and inconclusive echocardiography. Eur Heart J Cardiovasc Imaging, 2013; 14: 586-594.
Bensimhon L, Lavergne T, Hugonnet F et al. Whole body [(18)F] fluorodeoxyglucose positron emission tomography imaging for the diagnosis of pacemaker or implantable cardioverter defibrillator infection: a preliminary prospective study. Clin Microbiol Infect, 2011; 17: 836-844.
Sarrazin JF, Philippon F, Tessier M et al. Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections. J Am Coll Cardiol, 2012; 59: 1616-1625.
Leone S, Ravasio V, Durante-Mangoni E et al. Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian Study on Endocarditis. Infection, 2012; 40: 527-535.
Murdoch DR, Corey GR, Hoen B et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med, 2009; 169: 463-473.
Nadji G, Rusinaru D, Remadi JP et al. Heart failure in leftsided native valve infective endocarditis: characteristics, prognosis, and results of surgical treatment. Eur J Heart Fail, 2009; 11: 668-675.
Olmos C, Vilacosta I, Fernandez C et al. Contemporary epidemiology and prognosis of septic shock in infective endocarditis. Eur Heart J, 2013; 34: 1999-2006.
Garcia-Cabrera E, Fernandez-Hidalgo N, Almirante B et al. Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. Circulation, 2013; 127: 2272-2284.
Delahaye F, Alla F, Beguinot I et al. In-hospital mortality of infective endocarditis: prognostic factors and evolution over an 8-year period. Scand J Infect Dis, 2007; 39: 849-857.
Thuny F, Beurtheret S, Mancini J et al. The timing of surgery influences mortality and morbidity in adults with severe complicated infective endocarditis: a propensity analysis. Eur Heart J, 2011; 32: 2027-2033.
Chu VH, Cabell CH, Benjamin DK Jr et al. Early predictors of in-hospital death in infective endocarditis. Circulation, 2004; 109: 1745-1749.
San Roman JA, Lopez J, Vilacosta I et al. Prognostic stratification of patients with left-sided endocarditis determined at admission. Am J Med, 2007; 120: 369-367.
Chambers J, Sandoe J, Ray S et al. The infective endocarditis team: recommendations from an international working group. Heart, 2014; 100: 524-527.
Duval X, Alla F, Doco-Lecompte T et al. Diabetes mellitus and infective endocarditis: the insulin factor in patient morbidity and mortality. Eur Heart J, 2007; 28: 59-64.
Gelsomino S, Maessen JG, van der Veen F et al. Emergency surgery for native mitral valve endocarditis: the impact of septic and cardiogenic shock. Ann Thorac Surg, 2012; 93: 1469-1476.
Olmos C, Vilacosta I, Pozo E et al. Prognostic implications of diabetes in patients with left-sided endocarditis: findings from a large cohort study. Medicine (Baltimore), 2014; 93: 114-119.
Hoen B, Alla F, Selton-Suty C et al. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA, 2002; 288: 75-81.
Lopez J, Sevilla T, Vilacosta I et al. Prognostic role of persistent positive blood cultures after initiation of antibiotic therapy in left-sided infective endocarditis. Eur Heart J, 2013; 34: 1749-1754.
Revilla A, Lopez J, Vilacosta I et al. Clinical and prognostic profile of patients with infective endocarditis who need urgent surgery. Eur Heart J, 2007; 28: 65-71.
Mirabel M, Sonneville R, Hajage D et al. Long-term outcomes and cardiac surgery in critically ill patients with infective endocarditis. Eur Heart J, 2014; 35: 1195-1204.
Durack DT, Pelletier LL, Petersdorf RG. Chemotherapy of experimental streptococcal endocarditis. II. Synergism between penicillin and streptomycin against penicillin-sensitive streptococci. J Clin Invest, 1974; 53: 829-833.
Wilson WR, Geraci JE, Wilkowske CJ, Washington JA. Short-term intramuscular therapy with procaine penicillin plus streptomycin for infective endocarditis due to viridans streptococci. Circulation, 1978; 57: 1158-1161.
Cosgrove SE, Vigliani GA, Fowler VG Jr et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis, 2009; 48: 713-721.
Dahl A, Rasmussen RV, Bundgaard H et al. Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome. Circulation, 2013; 127: 1810-1817.
Miro JM, Garcia-de-la-Maria C, Armero Y et al. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother, 2009; 53: 4172-4177.
Garrigos C, Murillo O, Lora-Tamayo J et al. Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother, 2013; 57: 606-610.
Kullar R, Casapao AM, Davis SL et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother, 2013; 68: 2921-2926.
Dhand A, Bayer AS, Pogliano J et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis, 2011; 53: 158-163.
Miro JM, Entenza JM, del Rio A et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother, 2012; 56: 4511-4515.
Gould FK, Denning DW, Elliott TS et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother, 2012; 67: 269-289.
Westling K, Aufwerber E, Ekdahl C et al. Swedish guidelines for diagnosis and treatment of infective endocarditis. Scand J Infect Dis, 2007; 39: 929-946.
Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis, 1995; 21: 1406-1410.
Francioli P, Etienne J, Hoigne R et al. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. JAMA, 1992; 267: 264-267.
Sexton DJ, Tenenbaum MJ, Wilson WR et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis, 1998; 27: 1470-1474.
Cremieux AC, Maziere B, Vallois JM et al. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis, 1989; 159: 938-944.
Wilson AP, Gaya H. Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. J Antimicrob Chemother, 1996; 38: 507-521.
Venditti M, Tarasi A, Capone A et al. Teicoplanin in the treatment of enterococcal endocarditis: clinical and microbiological study. J Antimicrob Chemother, 1997; 40: 449-452.
Moet GJ, Dowzicky MJ, Jones RN. Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci. Diagn Microbiol Infect Dis, 2007; 57: 333-336.
Levy CS, Kogulan P, Gill VJ et al. Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. Clin Infect Dis, 2001; 33: 577-579.
Knoll B, Tleyjeh IM, Steckelberg JM et al. Infective endocarditis due to penicillin-resistant viridans group streptococci. Clin Infect Dis, 2007; 44: 1585-1592.
Hsu RB, Lin FY. Effect of penicillin resistance on presentation and outcome of nonenterococcal streptococcal infective endocarditis. Cardiology, 2006; 105: 234-239.
Shelburne SA III, Greenberg SB, Aslam S, Tweardy DJ. Successful ceftriaxone therapy of endocarditis due to penicillin non-susceptible viridans streptococci. J Infect, 2007; 54: e99-e101.
Nicolau DP, Freeman CD, Belliveau PP et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother, 1995; 39: 650-655.
Martinez E, Miro JM, Almirante B et al. Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults. Clin Infect Dis, 2002; 35: 130-139.
Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med, 1994; 331: 377-382.
Lefort A, Lortholary O, Casassus P et al. Comparison between adult endocarditis due to beta-hemolytic streptococci (serogroups A, B, C, and G) and Streptococcus milleri: a multicenter study in France. Arch Intern Med, 2002; 162: 2450-2456.
Sambola A, Miro JM, Tornos MP et al. Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature, 1962-1998. Clin Infect Dis, 2002; 34: 1576-1584.
Giuliano S, Caccese R, Carfagna P et al. Endocarditis caused by nutritionally variant streptococci: a case report and literature review. Infez Med, 2012; 20: 67-74.
Adam EL, Siciliano RF, Gualandro DM et al. Case series of infective endocarditis caused by Granulicatella species. Int J Infect Dis, 2015; 31: 56-58.
Anguera I, del Rio A, Miro JM et al. Staphylococcus lugdunensis infective endocarditis: description of 10 cases and analysis of native valve, prosthetic valve, and pacemaker lead endocarditis clinical profiles. Heart, 2005; 91: e10.
Cone LA, Sontz EM, Wilson JW, Mitruka SN. Staphylococcus capitis endocarditis due to a transvenous endocardial pacemaker infection: case report and review of Staphylococcus capitis endocarditis. Int J Infect Dis, 2005; 9: 335-339.
Sandoe JA, Kerr KG, Reynolds GW, Jain S. Staphylococcus capitis endocarditis: two cases and review of the literature. Heart, 1999; 82: e1.
Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med, 1982; 97: 496-503.
Apellaniz G, Valdes M, Perez R et al. Teicoplanin versus cloxacillin, cloxacillin-gentamycin and vancomycin in the treatment of experimental endocarditis caused by methicillin-sensitive Staphylococcus aureus. Enferm Infecc Microbiol Clin, 1991; 9: 208-210.
Casalta JP, Zaratzian C, Hubert S et al. Treatment of Staphylococcus aureus endocarditis with high doses of trimethoprim/sulfamethoxazole and clindamycin - preliminary report. Int J Antimicrob Agents, 2013; 42: 190-191.
Chirouze C, Cabell CH, Fowler VG Jr et al. Prognostic factors in 61 cases of Staphylococcus aureus prosthetic valve infective endocarditis from the International Collaboration on Endocarditis merged database. Clin Infect Dis, 2004; 38: 1323-1327.
Zimmerli W, Widmer AF, Blatter M et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA, 1998; 279: 1537-1541.
O'Connor S, Andrew P, Batt M, Becquemin JP. A systematic review and meta-analysis of treatments for aortic graft infection. J Vasc Surg, 2006; 44: 38-45.
Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother, 2008; 52: 2463-2467.
Howden BP, Johnson PD, Ward PB et al. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother, 2006; 50: 3039-3047.
Bae IG, Federspiel JJ, Miro JM et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis, 2009; 200: 1355-1366.
van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis, 2012; 54: 755-771.
Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med, 2006; 355: 653-665.
Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med, 2007; 120 (suppl. 1): S28-S33.
Carugati M, Bayer AS, Miro JM et al. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the International Collaboration on Endocarditis. Antimicrob Agents Chemother, 2013; 57: 6213-6222.
Moore CL, Osaki-Kiyan P, Haque NZ et al. Daptomycin versus vancomycin for bloodstream infections due to methicillinresistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis, 2012; 54: 51-58.
Murray KP, Zhao JJ, Davis SL et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration. 1 mg/L: a matched cohort study. Clin Infect Dis, 2013; 56: 1562-1569.
Gould IM, Miro JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents, 2013; 42: 202-210.
Rose WE, Leonard SN, Sakoulas G et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother, 2008; 52: 831-836.
del Rio A, Gasch O, Moreno A et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis, 2014; 59: 1105-1112.
Tattevin P, Boutoille D, Vitrat V et al. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Chemother, 2014; 69: 2010-2013.
Guignard B, Entenza JM, Moreillon P. Beta-lactams against methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol, 2005; 5: 479-489.
Vouillamoz J, Entenza JM, Feger C et al. Quinupristindalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolidelincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother, 2000; 44: 1789-1795.
Jang HC, Kim SH, Kim KH et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis, 2009; 49: 395-401.
Perichon B, Courvalin P. Synergism between beta-lactams and glycopeptides against VanA-type methicillin-resistant Staphylococcus aureus and heterologous expression of the vanA operon. Antimicrob Agents Chemother, 2006; 50: 3622-3630.
Chirouze C, Athan E, Alla F et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. Clin Microbiol Infect, 2013; 19: 1140-1147.
Reynolds R, Potz N, Colman M et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother, 2004; 53: 1018-1032.
Gavalda J, Len O, Miro JM et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med, 2007; 146: 574-579.
Fernandez-Hidalgo N, Almirante B, Gavalda J et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis, 2013; 56: 1261-1268.
Pericas JM, Cervera C, del Rio A et al. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect, 2014; 20: O1075-O1083.
Olaison L, Schadewitz K. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? Clin Infect Dis, 2002; 34: 159-166.
Miro JM, Pericas JM, del Rio A. A new era for treating Enterococcus faecalis endocarditis: ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: that is the question! Circulation, 2013; 127: 1763-1766.
Das M, Badley AD, Cockerill FR et al. Infective endocarditis caused by HACEK microorganisms. Annu Rev Med, 1997; 48: 25-33.
Paturel L, Casalta JP, Habib G et al. Actinobacillus actinomycetem-comitans endocarditis. Clin Microbiol Infect, 2004; 10: 98-118.
Morpeth S, Murdoch D, Cabell CH et al. Non-HACEK Gram-negative bacillus endocarditis. Ann Intern Med, 2007; 147: 829-835.
Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. Medicine (Baltimore), 2005; 84: 162-173.
Tattevin P, Watt G, Revest M et al. Update on blood culturenegative endocarditis. Med Mal Infect, 2015; 45: 1-8.
Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. Clin Microbiol Rev, 2001; 14: 177-207.
Ghigo E, Capo C, Aurouze M et al. Survival of Tropheryma whipplei, the agent of Whipple's disease, requires phagosome acidification. Infect Immun, 2002; 70: 1501-1506.
Rolain JM, Brouqui P, Koehler JE et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother, 2004; 48: 1921-1933.
Dajani AS, Taubert KA, Wilson W et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Circulation, 1997; 96: 358-366.
Raoult D, Fournier PE, Vandenesch F et al. Outcome and treatment of Bartonella endocarditis. Arch Intern Med, 2003; 163: 226-230.
Tattevin P, Revest M, Lefort A et al. Fungal endocarditis: current challenges. Int J Antimicrob Agents, 2014; 44: 290-294.
Kalokhe AS, Rouphael N, El Chami MF et al. Aspergillus endocarditis: a review of the literature. Int J Infect Dis, 2010; 14: e1040-e1047.
Smego RA Jr, Ahmad H. The role of fluconazole in the treatment of Candida endocarditis: a meta-analysis. Medicine (Baltimore), 2011; 90: 237-249.
Lye DC, Hughes A, O'Brien D, Athan E. Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. Eur J Clin Microbiol Infect Dis, 2005; 24 753-755.
Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol, 2007; 45: 3546-3548.
Paul M, Zemer-Wassercug N, Talker O et al. Are all beta-lactams similarly effective in the treatment of methicillinsensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect, 2011; 17: 1581-1586.
Tice AD, Rehm SJ, Dalovisio JR et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis, 2004; 38: 1651-1672.
Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis, 2001; 33: 203-209.
Cervera C, del Rio A, Garcia L et al. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. Enferm Infecc Microbiol Clin, 2011; 29: 587-592.
Duncan CJ, Barr DA, Ho A et al. Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis. J Antimicrob Chemother, 2013; 68: 1650-1654.
Hasbun R, Vikram HR, Barakat LA et al. Complicated left-sided native valve endocarditis in adults: risk classification for mortality. JAMA, 2003; 289: 1933-1940.
Aksoy O, Sexton DJ, Wang A et al. Early surgery in patients with infective endocarditis: a propensity score analysis. Clin Infect Dis, 2007; 44: 364-372.
Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ. Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis. JAMA, 2003; 290: 3207-3214.
Di Salvo G, Thuny F, Rosenberg V et al. Endocarditis in the elderly: clinical, echocardiographic, and prognostic features. Eur Heart J, 2003; 24: 1576-1583.
Olmos C, Vilacosta I, Fernandez C et al. Comparison of clinical features of left-sided infective endocarditis involving previously normal versus previously abnormal valves. Am J Cardiol, 2014; 114: 278-283.
Anguera I, Miro JM, Vilacosta I et al. Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J, 2005; 26: 288-297.
Piper C, Hetzer R, Korfer R et al. The importance of secondary mitral valve involvement in primary aortic valve endocarditis; the mitral kissing vegetation. Eur Heart J, 2002; 23: 79-86.
Vilacosta I, San Roman JA, Sarria C et al. Clinical, anatomic, and echocardiographic characteristics of aneurysms of the mitral valve. Am J Cardiol, 1999; 84: 110-113, A9.
Kiefer T, Park L, Tribouilloy C et al. Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. JAMA, 2011; 306: 2239-2247.
Kahveci G, Bayrak F, Mutlu B et al. Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with active infective endocarditis. Am J Cardiol, 2007; 99: 1429-1433.
Purcell JB, Patel M, Khera A et al. Relation of troponin elevation to outcome in patients with infective endocarditis. Am J Cardiol, 2008; 101: 1479-1481.
Shiue AB, Stancoven AB, Purcell JB et al. Relation of level of B-type natriuretic peptide with outcomes in patients with infective endocarditis. Am J Cardiol, 2010; 106: 1011-1015.
Lopez J, Sevilla T, Vilacosta I et al. Clinical significance of congestive heart failure in prosthetic valve endocarditis. A multicenter study with 257 patients. Rev Esp Cardiol (Engl Ed), 2013; 66: 384-390.
Habib G, Tribouilloy C, Thuny F et al. Prosthetic valve endocarditis: who needs surgery? A multicenter study of 104 cases. Heart, 2005; 91: 954-959.
Hubert S, Thuny F, Resseguier N et al. Prediction of symptomatic embolism in infective endocarditis: construction and validation of a risk calculator in a multicenter cohort. J Am Coll Cardiol, 2013; 62: 1384-1392.
Anguera I, Miro JM, Evangelista A et al. Periannular complications in infective endocarditis involving native aortic valves. Am J Cardiol, 2006; 98: 1254-1260.
Anguera I, Miro JM, San Roman JA et al. Periannular complications in infective endocarditis involving prosthetic aortic valves. Am J Cardiol, 2006; 98: 1261-1268.
Daniel W, Flaschkampf F. Infective endocarditis. In: Camm A, Luscher T, Serruys P et al. The ESC textbook of cardiovascular medicine. Blackwell, Oxford, 2006.
Leung DY, Cranney GB, Hopkins AP, Walsh WF. Role of transoesophageal echocardiography in the diagnosis and management of aortic root abscess. Br Heart J, 1994; 72: 175-181.
Graupner C, Vilacosta I, San Roman J et al. Periannular extension of infective endocarditis. J Am Coll Cardiol, 2002; 39: 1204-1211.
Lengyel M. The impact of transesophageal echocardiography on the management of prosthetic valve endocarditis: experience of 31 cases and review of the literature. J Heart Valve Dis, 1997; 6: 204-211.
Forteza A, Centeno J, Ospina V et al. Outcomes in aortic and mitral valve replacement with intervalvular fibrous body reconstruction. Ann Thorac Surg, 2015; 99: 838-845.
Chan KL. Early clinical course and long-term outcome of patients with infective endocarditis complicated by perivalvular abscess. CMAJ, 2002; 167: 19-24.
Tingleff J, Egeblad H, Gotzsche CO et al. Perivalvular cavities in endocarditis: abscesses versus pseudoaneurysms? A transesophageal Doppler echocardiographic study in 118 patients with endocarditis. Am Heart J, 1995; 130: 93-100.
Jenkins NP, Habib G, Prendergast BD. Aorto-cavitary fistulae in infective endocarditis: understanding a rare complication through collaboration. Eur Heart J, 2005; 26: 213-214.
Bashore TM, Cabell C, Fowler V Jr. Update on infective endocarditis. Curr Probl Cardiol, 2006; 31: 274-352.
Manzano MC, Vilacosta I, San Roman JA et al. Acute coronary syndrome in infective endocarditis. Rev Esp Cardiol, 2007; 60: 24-31.
Manne MB, Shrestha NK, Lytle BW et al. Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. Ann Thorac Surg, 2012; 93: 489-493.
Glazier JJ, Verwilghen J, Donaldson RM, Ross DN. Treatment of complicated prosthetic aortic valve endocarditis with annular abscess formation by homograft aortic root replacement. J Am Coll Cardiol, 1991; 17: 1177-1182.
Knosalla C, Weng Y, Yankah AC et al. Surgical treatment of active infective aortic valve endocarditis with associated periannular abscess - 11 year results. Eur Heart J, 2000; 21: 490-497.
Ellis ME, Al Abdely H, Sandridge A et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis, 2001; 32: 50-62.
Baddley JW, Benjamin DK Jr, Patel M et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis, 2008; 27: 519-529.
Bishara J, Leibovici L, Gartman-Israel D et al. Long-term outcome of infective endocarditis: the impact of early surgical intervention. Clin Infect Dis, 2001; 33: 1636-1643.
Remadi JP, Habib G, Nadji G et al. Predictors of death and impact of surgery in Staphylococcus aureus infective endocarditis. Ann Thorac Surg, 2007; 83: 1295-1302.
Di Salvo G, Habib G, Pergola V et al. Echocardiography predicts embolic events in infective endocarditis. J Am Coll Cardiol, 2001; 37: 1069-1076.
Steckelberg JM, Murphy JG, Ballard D et al. Emboli in infective endocarditis: the prognostic value of echocardiography. Ann Intern Med, 1991; 114: 635-640.
De Castro S, Magni G, Beni S et al. Role of transthoracic and transesophageal echocardiography in predicting embolic events in patients with active infective endocarditis involving native cardiac valves. Am J Cardiol, 1997; 80: 1030-1034.
Heinle S, Wilderman N, Harrison JK et al. Value of transthoracic echocardiography in predicting embolic events in active infective endocarditis. Duke Endocarditis Service. Am J Cardiol, 1994; 74: 799-801.
Rohmann S, Erbel R, Gorge G et al. Clinical relevance of vegetation localization by transoesophageal echocardiography in infective endocarditis. Eur Heart J, 1992; 13: 446-452.
Erbel R, Liu F, Ge J et al. Identification of high-risk subgroups in infective endocarditis and the role of echocardiography. Eur Heart J, 1995; 16: 588-602.
Sanfilippo AJ, Picard MH, Newell JB et al. Echocardiographic assessment of patients with infectious endocarditis: prediction of risk for complications. J Am Coll Cardiol, 1991; 18: 1191-1199.
Mugge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. J Am Coll Cardiol, 1989; 14: 631-638.
Dickerman SA, Abrutyn E, Barsic B et al. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J, 2007; 154: 1086-1094.
Cabell CH, Pond KK, Peterson GE et al. The risk of stroke and death in patients with aortic and mitral valve endocarditis. Am Heart J, 2001; 142: 75-80.
Tischler MD, Vaitkus PT. The ability of vegetation size on echocardiography to predict clinical complications: a meta-analysis. J Am Soc Echocardiogr, 1997; 10: 562-568.
Rohmann S, Erbel R, Darius H et al. Prediction of rapid versus prolonged healing of infective endocarditis by monitoring vegetation size. J Am Soc Echocardiogr, 1991; 4: 465-474.
Pergola V, Di Salvo G, Habib G et al. Comparison of clinical and echocardiographic characteristics of Streptococcus bovis endocarditis with that caused by other pathogens. Am J Cardiol, 2001; 88: 871-875.
Durante ME, Adinolfi LE, Tripodi MF et al. Risk factors for "major" embolic events in hospitalized patients with infective endocarditis. Am Heart J, 2003; 146: 311-316.
Kupferwasser LI, Hafner G, Mohr-Kahaly S et al. The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events. J Am Coll Cardiol, 1999; 33: 1365-1371.
Anavekar NS, Tleyjeh IM, Anavekar NS et al. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. Clin Infect Dis, 2007; 44: 1180-1186.
Chan KL, Dumesnil JG, Cujec B et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol, 2003; 42: 775-780.
Heiro M, Nikoskelainen J, Engblom E et al. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. Arch Intern Med, 2000; 160: 2781-2787.
Tleyjeh IM, Steckelberg JM, Georgescu G et al. The association between the timing of valve surgery and 6-month mortality in left-sided infective endocarditis. Heart, 2008; 94: 892-896.
Barsic B, Dickerman S, Krajinovic V et al. Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis, 2013; 56: 209-217.
Bannay A, Hoen B, Duval X et al. The impact of valve surgery on short- and long-term mortality in left-sided infective endocarditis: do differences in methodological approaches explain previous conflicting results? Eur Heart J, 2011; 32: 2003-2015.
Ruttmann E, Willeit J, Ulmer H et al. Neurological outcome of septic cardioembolic stroke after infective endocarditis. Stroke, 2006; 37: 2094-2099.
Yoshioka D, Sakaguchi T, Yamauchi T et al. Impact of early surgical treatment on postoperative neurologic outcome for active infective endocarditis complicated by cerebral infarction. Ann Thorac Surg, 2012; 94: 489-495.
Eishi K, Kawazoe K, Kuriyama Y et al. Surgical management of infective endocarditis associated with cerebral complications. Multicenter retrospective study in Japan. J Thorac Cardiovasc Surg, 1995; 110: 1745-1755.
Wilbring M, Irmscher L, Alexiou K et al. The impact of preoperative neurological events in patients suffering from native infective valve endocarditis. Interact Cardiovasc Thorac Surg, 2014; 18: 740-747.
Hui FK, Bain M, Obuchowski NA et al. Mycotic aneurysm detection rates with cerebral angiography in patients with infective endocarditis. J Neurointerv Surg, 2015; 7: 449-452.
Ducruet AF, Hickman ZL, Zacharia BE et al. Intracranial infectious aneurysms: a comprehensive review. Neurosurg Rev, 2010; 33: 37-46.
Peters PJ, Harrison T, Lennox JL. A dangerous dilemma: management of infectious intracranial aneurysms complicating endocarditis. Lancet Infect Dis, 2006; 6: 742-748.
Corr P, Wright M, Handler LC. Endocarditis-related cerebral aneurysms: radiologic changes with treatment. AJNR Am J Neuroradiol, 1995; 16: 745-748.
White PM, Teasdale EM, Wardlaw JM, Easton V. Intracranial aneurysms: CT angiography and MR angiography for detection prospective blinded comparison in a large patient cohort. Radiology, 2001; 219: 739-749.
Gonzalez I, Sarria C, Lopez J et al. Symptomatic peripheral mycotic aneurysms due to infective endocarditis: a contemporary profile. Medicine (Baltimore), 2014; 93: 42-52.
Bonfiglioli R, Nanni C, Morigi JJ et al. 18F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. Eur J Nucl Med Mol Imaging, 2013; 40: 1190-1196.
Akhyari P, Mehrabi A, Adhiwana A et al. Is simultaneous splenectomy an additive risk factor in surgical treatment for active endocarditis? Langenbecks Arch Surg, 2012; 397: 1261-1266.
Chou YH, Hsu CC, Tiu CM, Chang T. Splenic abscess: sonographic diagnosis and percutaneous drainage or aspiration. Gastrointest Radiol, 1992; 17: 262-266.
Katz LH, Pitlik S, Porat E et al. Pericarditis as a presenting sign of infective endocarditis: two case reports and review of the literature. Scand J Infect Dis, 2008; 40: 785-791.
Regueiro A, Falces C, Cervera C et al. Risk factors for pericardial effusion in native valve infective endocarditis and its influence on outcome. Am J Cardiol, 2013; 112: 1646-1651.
Ryu HM, Bae MH, Lee SH et al. Presence of conduction abnormalities as a predictor of clinical outcomes in patients with infective endocarditis. Heart Vessels, 2011; 26: 298-305.
Kitkungvan D, Denktas AE. Cardiac arrest and ventricular tachycardia from coronary embolism: an unusual presentation of infective endocarditis. Anadolu Kardiyol Derg, 2014; 14: 204-205.
Eisinger AJ. Atrial fibrillation in bacterial endocarditis. Br Heart J, 1971; 33: 739-741.
Gonzalez-Juanatey C, Gonzalez-Gay MA, Llorca J et al. Rheumatic manifestations of infective endocarditis in non-addicts. A 12-year study. Medicine (Baltimore), 2001; 80: 9-19.
Pigrau C, Almirante B, Flores X et al. Spontaneous pyogenic vertebral osteomyelitis and endocarditis: incidence, risk factors, and outcome. Am J Med, 2005; 118: 1287.
Bojalil R, Mazon-Gonzalez B, Carrillo-Cordova JR et al. Frequency and clinical significance of a variety of autoantibodies in patients with definite infective endocarditis. J Clin Rheumatol, 2012; 18: 67-70.
Ying CM, Yao DT, Ding HH, Yang CD. Infective endocarditis with antineutrophil cytoplasmic antibody: report of 13 cases and literature review. PLoS One, 2014; 9: e89777.
Nunes MC, Gelape CL, Ferrari TC. Profile of infective endocarditis at a tertiary care center in Brazil during a seven-year period: prognostic factors and in-hospital outcome. Int J Infect Dis, 2010; 14: e394-e398.
Tamura K. Clinical characteristics of infective endocarditis with vertebral osteomyelitis. J Infect Chemother, 2010; 16: 260-265.
Koslow M, Kuperstein R, Eshed I et al. The unique clinical features and outcome of infectious endocarditis and vertebral osteomyelitis coinfection. Am J Med, 2014; 127: 669.e9-669.e15.
Ojeda J, Lopez-Lopez L, Gonzalez A, Vila LM. Infective endocarditis initially presenting with a dermatomyositis-like syndrome. BMJ Case Rep, 2014 Jan 10; 2014. pii: bcr2013200865. doi:10.1136/bcr-2013-200865.
Vind SH, Hess S. Possible role of PET/CT in infective endocarditis. J Nucl Cardiol, 2010; 17: 516-519.
Ferraris L, Milazzo L, Ricaboni D et al. Profile of infective endocarditis observed from 2. BMC Infect Dis, 2013; 13: 545.
Le V, Gill S. Serious complications after infective endocarditis. Dan Med Bull, 2010; 57: A4192.
Tamura K, Arai H, Yoshizaki T. Long-term outcome of active infective endocarditis with renal insufficiency in cardiac surgery. Ann Thorac Cardiovasc Surg, 2012; 18: 216-221.
Conlon PJ, Jefferies F, Krigman HR et al. Predictors of prognosis and risk of acute renal failure in bacterial endocarditis. Clin Nephrol, 1998; 49: 96-101.
Majumdar A, Chowdhary S, Ferreira MA et al. Renal pathological findings in infective endocarditis. Nephrol Dial Transplant, 2000; 15: 1782-1787.
Colen TW, Gunn M, Cook E, Dubinsky T. Radiologic manifestations of extracardiac complications of infective endocarditis. Eur Radiol, 2008; 18: 2433-2445.
Mahr A, Batteux F, Tubiana S et al. Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol, 2014; 66: 1672-1677.
Nashef SA, Roques F, Sharples LD et al. EuroSCORE II. Eur J Cardiothorac Surg, 2012; 41: 734-744.
Gaca JG, Sheng S, Daneshmand MA et al. Outcomes for endocarditis surgery in North America: a simplified risk scoring system. J Thorac Cardiovasc Surg, 2011; 141: 98-106.
De Feo M, Cotrufo M, Carozza A et al. The need for a specific risk prediction system in native valve infective endocarditis surgery. Scientific World Journal, 2012; 2012: 307571.
Wang J, Liu H, Sun J et al. Varying correlation between 18F-fluorodeoxyglucose positron emission tomography and dynamic contrast-enhanced MRI in carotid atherosclerosis: implications for plaque inflammation. Stroke, 2014; 45: 1842-1845.
de Kerchove L, Vanoverschelde JL, Poncelet A et al. Reconstructive surgery in active mitral valve endocarditis: feasibility, safety and durability. Eur J Cardiothorac Surg, 2007; 31: 592-599.
de Kerchove L, Price J, Tamer S et al. Extending the scope of mitral valve repair in active endocarditis. J Thorac Cardiovasc Surg, 2012; 143 (suppl.): S91-S95.
Meszaros K, Nujic S, Sodeck GH et al. Long-term results after operations for active infective endocarditis in native and prosthetic valves. Ann Thorac Surg, 2012; 94: 1204-1210.
Edwards MB, Ratnatunga CP, Dore CJ, Taylor KM. Thirty-day mortality and longterm survival following surgery for prosthetic endocarditis: a study from the UK heart valve registry. Eur J Cardiothorac Surg, 1998; 14: 156-164.
Dreyfus G, Serraf A, Jebara VA et al. Valve repair in acute endocarditis. Ann Thorac Surg, 1990; 49: 706-711.
Shang E, Forrest GN, Chizmar T et al. Mitral valve infective endocarditis: benefit of early operation and aggressive use of repair. Ann Thorac Surg, 2009; 87: 1728-1733.
David TE, Regesta T, Gavra G et al. Surgical treatment of paravalvular abscess: long-term results. Eur J Cardiothorac Surg, 2007; 31: 43-48.
Nataf P, Jault F, Dorent R et al. Extra-annular procedures in the surgical management of prosthetic valve endocarditis. Eur Heart J, 1995; 16 (suppl. B): 99-102.
Vistarini N, d'Alessandro C, Aubert S et al. Surgery for infective endocarditis on mitral annulus calcification. J Heart Valve Dis, 2007; 16: 611-616.
Ali M, Iung B, Lansac E et al. Homograft replacement of the mitral valve: eight-year results. J Thorac Cardiovasc Surg, 2004; 128: 529-534.
Kabbani S, Jamil H, Nabhani F et al. Analysis of 92 mitral pulmonary autograft replacement (Ross II) operations. J Thorac Cardiovasc Surg, 2007; 134: 902-908.
David TE. Aortic valve repair for active infective endocarditis. Eur J Cardiothorac Surg, 2012; 42: 127-128.
Mayer K, Aicher D, Feldner S et al. Repair versus replacement of the aortic valve in active infective endocarditis. Eur J Cardiothorac Surg, 2012; 42: 122-127.
Lopes S, Calvinho P, de Oliveira F, Antunes M. Allograft aortic root replacement in complex prosthetic endocarditis. Eur J Cardiothorac Surg, 2007; 32: 126-130.
Musci M, Weng Y, Hubler M et al. Homograft aortic root replacement in native or prosthetic active infective endocarditis: twenty-year single-center experience. J Thorac Cardiovasc Surg, 2010; 139: 665-673.
Klieverik LM, Yacoub MH, Edwards S et al. Surgical treatment of active native aortic valve endocarditis with allografts and mechanical prostheses. Ann Thorac Surg, 2009; 88: 1814-1821.
Avierinos JF, Thuny F, Chalvignac V et al. Surgical treatment of active aortic endocarditis: homografts are not the cornerstone of outcome. Ann Thorac Surg, 2007; 84: 1935-1942.
Takkenberg JJ, Klieverik LM, Bekkers JA et al. Allografts for aortic valve or root replacement: insights from an 18-year single-center prospective follow-up study. Eur J Cardiothorac Surg, 2007; 31: 851-859.
Obadia JF, Henaine R, Bergerot C et al. Monobloc aorto-mitral homograft or mechanical valve replacement: a new surgical option for extensive bivalvular endocarditis. J Thorac Cardiovasc Surg, 2006; 131: 243-245.
Prat A, Fabre OH, Vincentelli A et al. Ross operation and mitral homograft for aortic and tricuspid valve endocarditis. Ann Thorac Surg, 1998; 65: 1450-1452.
Schmidtke C, Dahmen G, Sievers HH. Subcoronary Ross procedure in patients with active endocarditis. Ann Thorac Surg, 2007; 83: 36-39.
Aymami M, Revest M, Piau C et al. Heart transplantation as salvage treatment of intractable infective endocarditis. Clin Microbiol Infect, 2015; 21: 371.e1-371.e4.
Butchart EG, Gohlke-Barwolf C, Antunes MJ et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J, 2005; 26: 2463-2471.
David TE, Gavra G, Feindel CM et al. Surgical treatment of active infective endocarditis: a continued challenge. J Thorac Cardiovasc Surg, 2007; 133: 144-149.
Heiro M, Helenius H, Hurme S et al. Long-term outcome of infective endocarditis: a study on patients surviving over one year after the initial episode treated in a Finnish teaching hospital during 25 years. BMC Infect Dis, 2008; 8: 49.
Martinez-Selles M, Munoz P, Estevez A et al. Long-term outcome of infective endocarditis in non-intravenous drug users. Mayo Clin Proc, 2008; 83: 1213-1217.
Fernandez-Hidalgo N, Almirante B, Tornos P et al. Immediate and long-term outcome of left-sided infective endocarditis. A 12-year prospective study from a contemporary cohort in a referral hospital. Clin Microbiol Infect, 2012; 18: E522-E530.
Ternhag A, Cederstrom A, Torner A, Westling K. A nationwide cohort study of mortality risk and long-term prognosis in infective endocarditis in Sweden. PLoS One, 2013; 8: e67519.
Mokhles MM, Ciampichetti I, Head SJ et al. Survival of surgically treated infective endocarditis: a comparison with the general Dutch population. Ann Thorac Surg, 2011; 91: 1407-1412.
Fedoruk LM, Jamieson WR, Ling H et al. Predictors of recurrence and reoperation for prosthetic valve endocarditis after valve replacement surgery for native valve endocarditis. J Thorac Cardiovasc Surg, 2009; 137: 326-333.
Alagna L, Park LP, Nicholson BP et al. Repeat endocarditis: analysis of risk factors based on the International Collaboration on Endocarditis - Prospective Cohort Study. Clin Microbiol Infect, 2014; 20: 566-575.
Kaiser SP, Melby SJ, Zierer A et al. Long-term outcomes in valve replacement surgery for infective endocarditis. Ann Thorac Surg, 2007; 83: 30-35.
Heiro M, Helenius H, Makila S et al. Infective endocarditis in a Finnish teaching hospital: a study on 326 episodes treated during 1980-2004. Heart, 2006; 92: 1457-1462.
Sabik JF, Lytle BW, Blackstone EH et al. Aortic root replacement with cryopreserved allograft for prosthetic valve endocarditis. Ann Thorac Surg, 2002; 74: 650-659.
Hagl C, Galla JD, Lansman SL et al. Replacing the ascending aorta and aortic valve for acute prosthetic valve endocarditis: is using prosthetic material contraindicated? Ann Thorac Surg, 2002; 74: S1781-S1785.
Chambers JB, Ray S, Prendergast B et al. Specialist valve clinics: recommendations from the British Heart Valve Society working group on improving quality in the delivery of care for patients with heart valve disease. Heart, 2013; 99: 1714-1716.
Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med, 1996; 335: 407-416.
Moreillon P, Que YA. Infective endocarditis. Lancet, 2004; 363: 139-149.
Wang A, Athan E, Pappas PA et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA, 2007; 297: 1354-1361.
Habib G, Thuny F, Avierinos JF. Prosthetic valve endocarditis: current approach and therapeutic options. Prog Cardiovasc Dis, 2008; 50: 274-281.
Lopez J, Revilla A, Vilacosta I et al. Definition, clinical profile, microbiological spectrum, and prognostic factors of early-onset prosthetic valve endocarditis. Eur Heart J, 2007; 28: 760-765.
Mahesh B, Angelini G, Caputo M et al. Prosthetic valve endocarditis. Ann Thorac Surg, 2005; 80: 1151-1158.
Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H et al. Infective endocarditis following transcatheter aortic valve implantation: results from a large multicenter registry. Circulation, 2015; 131: 1566-1574.
Pericas JM, Llopis J, Cervera C et al. Infective endocarditis in patients with an implanted transcatheter aortic valve: Clinical characteristics and outcome of a new entity. J Infect, 2015; 70: 565-576.
Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med, 1994; 96: 200-209.
Lamas CC, Eykyn SJ. Suggested modifications to the Duke criteria for the clinical diagnosis of native valve and prosthetic valve endocarditis: analysis of 118 pathologically proven cases. Clin Infect Dis, 1997; 25: 713-719.
Perez-Vazquez A, Farinas MC, Garcia-Palomo JD et al. Evaluation of the Duke criteria in 93 episodes of prosthetic valve endocarditis: could sensitivity be improved? Arch Intern Med, 2000; 160: 1185-1191.
Tornos P, Almirante B, Olona M et al. Clinical outcome and long-term prognosis of late prosthetic valve endocarditis: a 20-year experience. Clin Infect Dis, 1997; 24: 381-386.
Akowuah EF, Davies W, Oliver S et al. Prosthetic valve endocarditis: early and late outcome following medical or surgical treatment. Heart, 2003; 89: 269-272.
John MD, Hibberd PL, Karchmer AW et al. Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis, 1998; 26: 1302-1309.
Wolff M, Witchitz S, Chastang C et al. Prosthetic valve endocarditis in the ICU. Prognostic factors of overall survival in a series of 122 cases and consequences for treatment decision. Chest, 1995; 108: 688-694.
Gordon SM, Serkey JM, Longworth DL et al. Early onset prosthetic valve endocarditis: the Cleveland Clinic experience 1992-1997. Ann Thorac Surg, 2000; 69: 1388-1392.
Sohail MR, Martin KR, Wilson WR et al. Medical versus surgical management of Staphylococcus aureus prosthetic valve endocarditis. Am J Med, 2006; 119: 147-154.
Wang A, Pappas P, Anstrom KJ et al. The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort. Am Heart J, 2005; 150: 1086-1091.
Truninger K, Attenhofer Jost CH, Seifert B et al. Long term follow up of prosthetic valve endocarditis: what characteristics identify patients who were treated successfully with antibiotics alone? Heart, 1999; 82: 714-720.
Hill EE, Herregods MC, Vanderschueren S et al. Management of prosthetic valve infective endocarditis. Am J Cardiol, 2008; 101: 1174-1178.
Bonow RO, Carabello BA, Chatterjee K et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol, 2008; 52: e523-e661.
Rundstrom H, Kennergren C, Andersson R et al. Pacemaker endocarditis during 18 years in Goteborg. Scand J Infect Dis, 2004; 36: 674-679.
Greenspon AJ, Patel JD, Lau E et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol, 2011; 58: 1001-1006.
Baddour LM, Epstein AE, Erickson CC et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation, 2010; 121: 458-477.
Baddour LM, Bettmann MA, Bolger AF et al. Nonvalvular cardiovascular device-related infections. Circulation, 2003; 108: 2015-2031.
Uslan DZ, Sohail MR, St Sauver JL et al. Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch Intern Med, 2007; 167: 669-675.
Nof E, Epstein LM. Complications of cardiac implants: handling device infections. Eur Heart J, 2013; 34: 229-236.
Sohail MR, Uslan DZ, Khan AH et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol, 2007; 49: 1851-1859.
Klug D, Balde M, Pavin D et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation, 2007; 116: 1349-1355.
Bloom H, Heeke B, Leon A et al. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol, 2006; 29: 142-145.
Lekkerkerker JC, van Nieuwkoop C, Trines SA et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart, 2009; 95: 715-720.
Johansen JB, Nielsen JC, Arnsbo P et al. Higher incidence of pacemaker infection after replacement than after implantation: experiences from 36,076 consecutive patients. Heart Rhythm, 2006; 3: S102-S103.
Gould PA, Krahn AD. Complications associated with implantable cardioverter defibrillator replacement in response to device advisories. JAMA, 2006; 295: 1907-1911.
Da Costa A, Kirkorian G, Cucherat M et al. Antibiotic prophylaxis for permanent pacemaker implantation: a meta-analysis. Circulation, 1998; 97: 1796-1801.
Al Khatib SM, Lucas FL, Jollis JG et al. The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. J Am Coll Cardiol, 2005; 46: 1536-1540.
Villamil CI, Rodriguez FM, Van den Eynde CA et al. Permanent transvenous pacemaker infections: An analysis of 59 cases. Eur J Intern Med, 2007; 18: 484-488.
Bongiorni MG, Tascini C, Tagliaferri E et al. Microbiology of cardiac implantable electronic device infections. Europace, 2012; 14: 1334-1339.
Tarakji KG, Chan EJ, Cantillon DJ et al. Cardiac implantable electronic device infections: presentation, management, and patient outcomes. Heart Rhythm, 2010; 7: 1043-1047.
Abraham J, Mansour C, Veledar E et al. Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am Heart J, 2004; 147: 536-539.
del Rio A, Anguera I, Miro JM et al. Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest, 2003; 124: 1451-1459.
Cacoub P, Leprince P, Nataf P et al. Pacemaker infective endocarditis. Am J Cardiol, 1998; 82: 480-484.
Klug D, Lacroix D, Savoye C et al. Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. Circulation, 1997; 95: 2098-2107.
Vilacosta I, Sarria C, San Roman JA et al. Usefulness of transesophageal echocardiography for diagnosis of infected transvenous permanent pacemakers. Circulation, 1994; 89: 2684-2687.
Victor F, de Place C, Camus C et al. Pacemaker lead infection: echocardiographic features, management, and outcome. Heart, 1999; 81: 82-87.
Golzio PG, Fanelli AL, Vinci M et al. Lead vegetations in patients with local and systemic cardiac device infections: prevalence, risk factors, and therapeutic effects. Europace, 2013; 15: 89-100.
Bongiorni MG, Di Cori A, Soldati E et al. Intracardiac echocardiography in patients with pacing and defibrillating leads: a feasibility study. Echocardiography, 2008; 25: 632-638.
Narducci ML, Pelargonio G, Russo E et al. Usefulness of intracardiac echocardiography for the diagnosis of cardiovascular implantable electronic device-related endocarditis. J Am Coll Cardiol, 2013; 61: 1398-1405.
Dalal A, Asirvatham SJ, Chandrasekaran K et al. Intracardiac echocardiography in the detection of pacemaker lead endocarditis. J Am Soc Echocardiogr, 2002; 15: 1027-1028.
Erba PA, Sollini M, Conti U et al. Radiolabeled WBC scintigraphy in the diagnostic workup of patients with suspected device-related infections. JACC Cardiovasc Imaging, 2013; 6: 1075-1086.
Ploux S, Riviere A, Amraoui S et al. Positron emission tomography in patients with suspected pacing system infections may play a critical role in difficult cases. Heart Rhythm, 2011; 8: 1478-1481.
Sohail MR, Uslan DZ, Khan AH et al. Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. Mayo Clin Proc, 2008; 83: 46-53.
Jan E, Camou F, Texier-Maugein J et al. Microbiologic characteristics and in vitro susceptibility to antimicrobials in a large population of patients with cardiovascular implantable electronic device infection. J Cardiovasc Electrophysiol, 2012; 23: 375-381.
Tumbarello M, Pelargonio G, Trecarichi EM et al. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis caused by staphylococcal small-colony variants. Clin Infect Dis, 2012; 54: 1516-1517.
Tascini C, Bongiorni MG, Di Cori A et al. Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal. Heart Lung, 2012; 41: e24-e30.
Durante-Mangoni E, Casillo R, Bernardo M et al. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis, 2012; 54: 347-354.
Wilkoff BL, Love CJ, Byrd CL et al. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). Heart Rhythm, 2009; 6: 1085-1104.
Pichlmaier M, Knigina L, Kutschka I et al. Complete removal as a routine treatment for any cardiovascular implantable electronic device-associated infection. J Thorac Cardiovasc Surg, 2011; 142: 1482-1490.
Grammes JA, Schulze CM, Al Bataineh M et al. Percutaneous pacemaker and implantable cardioverter-defibrillator lead extraction in 100 patients with intracardiac vegetations defined by transesophageal echocardiogram. J Am Coll Cardiol, 2010; 55: 886-894.
Maytin M, Jones SO, Epstein LM. Long-term mortality after transvenous lead extraction. Circ Arrhythm Electrophysiol, 2012; 5: 252-257.
Di Cori A, Bongiorni MG, Zucchelli G et al. Transvenous extraction performance of expanded polytetrafluoroethylene covered ICD leads in comparison to traditional ICD leads in humans. Pacing Clin Electrophysiol, 2010; 33: 1376-1381.
Di Cori A, Bongiorni MG, Zucchelli G et al. Large, single-center experience in transvenous coronary sinus lead extraction: procedural outcomes and predictors for mechanical dilatation. Pacing Clin Electrophysiol, 2012; 35: 215-222.
Maytin M, Carrillo RG, Baltodano P et al. Multicenter experience with transvenous lead extraction of active fixation coronary sinus leads. Pacing Clin Electrophysiol, 2012; 35: 641-647.
Deharo JC, Bongiorni MG, Rozkovec A et al. Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper. Europace, 2012; 14: 124-134.
Meier-Ewert HK, Gray ME, John RM. Endocardial pacemaker or defibrillator leads with infected vegetations: a single-center experience and consequences of transvenous extraction. Am Heart J, 2003; 146: 339-344.
Ruttmann E, Hangler HB, Kilo J et al. Transvenous pacemaker lead removal is safe and effective even in large vegetations: an analysis of 53 cases of pacemaker lead endocarditis. Pacing Clin Electrophysiol, 2006; 29: 231-236.
Gaynor SL, Zierer A, Lawton JS et al. Laser assistance for extraction of chronically implanted endocardial leads: infectious versus noninfectious indications. Pacing Clin Electrophysiol, 2006; 29: 1352-1358.
Braun MU, Rauwolf T, Bock M et al. Percutaneous lead implantation connected to an external device in stimulationdependent patients with systemic infection - a prospective and controlled study. Pacing Clin Electrophysiol, 2006; 29: 875-879.
Kornberger A, Schmid E, Kalender G et al. Bridge to recovery or permanent system implantation: an eight-year single-center experience in transvenous semipermanent pacing. Pacing Clin Electrophysiol, 2013; 36: 1096-1103.
Kawata H, Pretorius V, Phan H et al. Utility and safety of temporary pacing using active fixation leads and externalized re-usable permanent pacemakers after lead extraction. Europace, 2013; 15: 1287-1291.
Pecha S, Aydin MA, Yildirim Y et al. Transcutaneous lead implantation connected to an externalized pacemaker in patients with implantable cardiac defibrillator/pacemaker infection and pacemaker dependency. Europace, 2013; 15: 1205-1209.
Mourvillier B, Trouillet JL, Timsit JF et al. Infective endocarditis in the intensive care unit: clinical spectrum and prognostic factors in 228 consecutive patients. Intensive Care Med, 2004; 30: 2046-2052.
Sonneville R, Mirabel M, Hajage D et al. Neurologic complications and outcomes of infective endocarditis in critically ill patients: the ENDOcardite en REAnimation prospective multicenter study. Crit Care Med, 2011; 39: 1474-1481.
Fernandez Guerrero ML, Alvarez B, Manzarbeitia F, Renedo G. Infective endocarditis at autopsy: a review of pathologic manifestations and clinical correlates. Medicine (Baltimore), 2012; 91: 152-164.
Saydain G, Singh J, Dalal B et al. Outcome of patients with injection drug use-associated endocarditis admitted to an intensive care unit. J Crit Care, 2010; 25: 248-253.
McDonald JR. Acute infective endocarditis. Infect Dis Clin North Am, 2009; 23: 643-664.
Karth G, Koreny M, Binder T et al. Complicated infective endocarditis necessitating ICU admission: clinical course and prognosis. Crit Care, 2002; 6: 149-154.
Glockner A, Cornely OA. Invasive candidiasis in non-neutropenic adults: guideline-based management in the intensive care unit. Anaesthetist, 2013; 62: 1003-1009.
Dellinger RP, Levy MM, Rhodes A et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med, 2013; 39: 165-228.
Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clin Infect Dis, 2000; 30: 374-379.
Wilson LE, Thomas DL, Astemborski J et al. Prospective study of infective endocarditis among injection drug users. J Infect Dis, 2002; 185: 1761-1766.
Gebo KA, Burkey MD, Lucas GM et al. Incidence of, risk factors for, clinical presentation, and 1-year outcomes of infective endocarditis in an urban HIV cohort. J Acquir Immune Defic Syndr, 2006; 43: 426-432.
Cooper HL, Brady JE, Ciccarone D et al. Nationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditis. Clin Infect Dis, 2007; 45: 1200-1203.
Miro JM, del Rio A, Mestres CA. Infective endocarditis and cardiac surgery in intravenous drug abusers and HIV-1 infected patients. Cardiol Clin, 2003; 21: 167-184.
Sousa C, Botelho C, Rodrigues D et al. Infective endocarditis in intravenous drug abusers: an update. Eur J Clin Microbiol Infect Dis, 2012; 31: 2905-2910.
Carozza A, De Santo LS, Romano G et al. Infective endocarditis in intravenous drug abusers: patterns of presentation and long-term outcomes of surgical treatment. J Heart Valve Dis, 2006; 15: 125-131.
Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. Ann Intern Med, 1992; 117: 560-566.
Moss R, Munt B. Injection drug use and right sided endocarditis. Heart, 2003; 89: 577-581.
Gottardi R, Bialy J, Devyatko E et al. Midterm follow-up of tricuspid valve reconstruction due to active infective endocarditis. Ann Thorac Surg, 2007; 84: 1943-1948.
Gaca JG, Sheng S, Daneshmand M et al. Current outcomes for tricuspid valve infective endocarditis surgery in North America. Ann Thorac Surg, 2013; 96: 1374-1381.
San Roman JA, Vilacosta I, Lopez J et al. Role of transthoracic and transesophageal echocardiography in right-sided endocarditis: one echocardiographic modality does not fit all. J Am Soc Echocardiogr, 2012; 25: 807-814.
San Roman JA, Vilacosta I, Zamorano JL et al. Transesophageal echocardiography in right-sided endocarditis. J Am Coll Cardiol, 1993; 21:1226-1230.
Winslow T, Foster E, Adams JR, Schiller NB. Pulmonary valve endocarditis: improved diagnosis with biplane transesophageal echocardiography. J Am Soc Echocardiogr, 1992; 5: 206-210.
Botsford KB, Weinstein RA, Nathan CR, Kabins SA. Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts. J Infect Dis, 1985; 151: 209-216.
Martin-Davila P, Navas E, Fortun J et al. Analysis of mortality and risk factors associated with native valve endocarditis in drug users: the importance of vegetation size. Am Heart J, 2005; 150: 1099-1106.
Bisbe J, Miro JM, Latorre X et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. Clin Infect Dis, 1992; 15: 910-923.
Ribera E, Gomez-Jimenez J, Cortes E et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med, 1996; 125: 969-974.
Fortun J, Perez-Molina JA, Anon MT et al. Right-sided endocarditis caused by Staphylococcus aureus in drug abusers. Antimicrob Agents Chemother, 1995; 39: 525-528.
Pulvirenti JJ, Kerns E, Benson C et al. Infective endocarditis in injection drug users: importance of human immunodeficiency virus serostatus and degree of immunosuppression. Clin Infect Dis, 1996; 22: 40-45.
Al Omari A, Cameron DW, Lee C, Corrales-Medina VF. Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review. BMC Infect Dis, 2014; 14: 140.
Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol, 2004; 42: 2398-2402.
Akinosoglou K, Apostolakis E, Koutsogiannis N et al. Rightsided infective endocarditis: surgical management. Eur J Cardiothorac Surg, 2012; 42: 470-479.
Moller JH, Anderson RC. 1,000 consecutive children with a cardiac malformation with 26- to 37-year follow-up. Am J Cardiol, 1992; 70: 661-667.
Niwa K, Nakazawa M, Tateno S et al. Infective endocarditis in congenital heart disease: Japanese national collaboration study. Heart, 2005; 91: 795-800.
Verheugt CL, Uiterwaal CS, van der Velde ET et al. Turning 18 with congenital heart disease: prediction of infective endocarditis based on a large population. Eur Heart J, 2011; 32: 1926-1934.
Rushani D, Kaufman JS, Ionescu-Ittu R et al. Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors. Circulation, 2013; 128: 1412-1419.
Michel PL, Acar J. Native cardiac disease predisposing to infective endocarditis. Eur Heart J, 1995; 16 (suppl. B): 2-6.
De Gevigney G, Pop C, Delahaye JP. The risk of infective endocarditis after cardiac surgical and interventional procedures. Eur Heart J, 1995; 16 (suppl. B): 7-14.
Roder BL, Wandall DA, Espersen F et al. Neurologic manifestations in Staphylococcus aureus endocarditis: a review of 260 bacteremic cases in nondrug addicts. Am J Med, 1997; 102: 379-386.
Baek JE, Park SJ, Woo SB et al. Changes in patient characteristics of infective endocarditis with congenital heart disease: 25 years experience in a single institution. Korean Circ J, 2014; 44: 37-41.
Webb R, Voss L, Roberts S et al. Infective endocarditis in New Zealand children 1994-2012. Pediatr Infect Dis J, 2014; 33: 437-442.
Di Filippo S, Delahaye F, Semiond B et al. Current patterns of infective endocarditis in congenital heart disease. Heart, 2006; 92: 1490-1495.
Li W, Somerville J. Infective endocarditis in the grown-up congenital heart (GUCH) population. Eur Heart J, 1998; 19: 166-173.
Gabriel HM, Heger M, Innerhofer P et al. Long-term outcome of patients with ventricular septal defect considered not to require surgical closure during childhood. J Am Coll Cardiol, 2002; 39: 1066-1071.
Yoshinaga M, Niwa K, Niwa A et al. Risk factors for in-hospital mortality during infective endocarditis in patients with congenital heart disease. Am J Cardiol, 2008; 101: 114-118.
Warnes CA, Williams RG, Bashore TM et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration with the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol, 2008; 52: e143-e263.
Moons P, De Volder E, Budts W et al. What do adult patients with congenital heart disease know about their disease, treatment, and prevention of complications? A call for structured patient education. Heart, 2001; 86: 74-80.
Gersony WM, Hayes CJ, Driscoll DJ et al. Bacterial endocarditis in patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect. Circulation, 1993; 87: I121-I126.
Thilen U, Astrom-Olsson K. Does the risk of infective endarteritis justify routine patent ductus arteriosus closure? Eur Heart J, 1997; 18: 503-506.
Foley M. Cardiac disease. In: Dildy G, Belfort M, Saade G, Phelan J et al. Critical care obstetrics, 4th ed. Blackwell, Oxford, 2004: 252-274.
Montoya ME, Karnath BM, Ahmad M. Endocarditis during pregnancy. South Med J, 2003; 96: 1156-1157.
Roos-Hesselink JW, Ruys TP, Stein JI et al. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J, 2013; 34: 657-665.
Morissens M, Viart P, Tecco L et al. Does congenital heart disease severely jeopardise family life and pregnancies? Obstetrical history of women with congenital heart disease in a single tertiary centre. Cardiol Young, 2013; 23: 41-46.
Aggarwal N, Suri V, Kaur H et al. Retrospective analysis of outcome of pregnancy in women with congenital heart disease: single centre experience from North India. Aust N Z J Obstet Gynaecol, 2009; 49: 376-381.
Mazibuko B, Ramnarain H, Moodley J. An audit of pregnant women with prosthetic heart valves at a tertiary hospital in South Africa: a five-year experience. Cardiovasc J Afr, 2012; 23: 216-221.
Ong E, Mechtouff L, Bernard E et al. Thrombolysis for stroke caused by infective endocarditis: an illustrative case and review of the literature. J Neurol, 2013; 260: 1339-1342.
Tornos P, Almirante B, Mirabet S et al. Infective endocarditis due to Staphylococcus aureus: deleterious effect of anticoagulant therapy. Arch Intern Med, 1999; 159: 473-475.
Snygg-Martin U, Rasmussen RV, Hassager C et al. Warfarin therapy and incidence of cerebrovascular complications in left-sided native valve endocarditis. Eur J Clin Microbiol Infect Dis, 2011; 30: 151-157.
Kupferwasser LI, Yeaman MR, Shapiro SM et al. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation, 1999; 99: 2791-2797.
Habib A, Irfan M, Baddour LM et al. Impact of prior aspirin therapy on clinical manifestations of cardiovascular implantable electronic device infections. Europace, 2013; 15: 227-235.
Chan KL, Tam J, Dumesnil JG et al. Effect of long-term aspirin use on embolic events in infective endocarditis. Clin Infect Dis, 2008; 46: 37-41.
Snygg-Martin U, Rasmussen RV, Hassager C et al. The relationship between cerebrovascular complications and previously established use of antiplatelet therapy in left-sided infective endocarditis. Scand J Infect Dis, 2011; 43: 899-904.
Silbiger JJ. The valvulopathy of non-bacterial thrombotic endocarditis. J Heart Valve Dis, 2009; 18: 159-166.
Zamorano J, Sanz J, Almeria C et al. Differences between endocarditis with true negative blood cultures and those with previous antibiotic treatment. J Heart Valve Dis 2003;12:256-260.
Mazokopakis EE, Syros PK, Starakis IK. Nonbacterial thrombotic endocarditis (marantic endocarditis) in cancer patients. Cardiovasc Hematol Disord Drug Targets, 2010; 10: 84-86.
Dutta T, Karas MG, Segal AZ, Kizer JR. Yield of transesophageal echocardiography for nonbacterial thrombotic endocarditis and other cardiac sources of embolism in cancer patients with cerebral ischemia. Am J Cardiol, 2006; 97: 894-898.
Zamorano J, de Isla LP, Moura L et al. Impact of echocardiography in the short- and long-term prognosis of patients with infective endocarditis and negative blood cultures. J Heart Valve Dis, 2004; 13: 997-1004.
Giles I, Khamashta M, D'Cruz D, Cohen H. A new dawn of anticoagulation for patients with antiphospholipid syndrome? Lupus, 2012; 21: 1263-1265.
Thomsen RW, Farkas DK, Friis S et al. Endocarditis and risk of cancer: a Danish nationwide cohort study. Am J Med, 2013; 126: 58-67.
Gupta A, Madani R, Mukhtar H. Streptococcus bovis endocarditis, a silent sign for colonic tumour. Colorectal Dis, 2010; 12: 164-171.
Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis, 2011; 53: 870-878.
Ferrari A, Botrugno I, Bombelli E et al. Colonoscopy is mandatory after Streptococcus bovis endocarditis: a lesson still not learned. Case report. World J Surg Oncol, 2008; 6: 49.
Darjee R, Gibb AP. Serological investigation into the association between Streptococcus bovis and colonic cancer. J Clin Pathol, 1993; 46: 1116-1119.
